GILD — GILEAD SCIENCES, INC. catalysts
Next verified catalyst
2027-01-01 — Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcera · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01 (month) in 2mo
ESTIMATED |
READOUT
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Act
Phase 2 · Ulcerative Colitis |
GILD GILEAD SCIENCES, INC. | Tilpisertib Fosmecarbil |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-02 (month) in 3mo
ESTIMATED |
READOUT
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
Phase 3 · Triple Negative Breast Cancer, PD-L1 Positive |
GILD GILEAD SCIENCES, INC. | Sacituzumab Govitecan-hziy, Pembrolizuma |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participa
Phase 2 · Non-small Cell Lung Cancer |
GILD GILEAD SCIENCES, INC. | Sacituzumab Govitecan-hziy (SG), Pembrol |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
Study of Novel Treatment Combination Therapies in Participants With Head and Nec
Phase 2 · Head and Neck Squamous Cell Carcinoma |
GILD GILEAD SCIENCES, INC. | Domvanalimab, Zimberelimab, Paclitaxel, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-ex
Phase 2 · HIV-1-infection |
GILD GILEAD SCIENCES, INC. | Oral Lenacapavir, Subcutaneous Lenacapav |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|